Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 11, Issue 3, 2009, Pages

  Hueber, Wolfgang ^a,b   Tomooka, Beren H ^a,b   Batliwalla, Franak ^c   Li, Wentian ^c   Monach, Paul A ^d,e   Tibshirani, Robert J ^f   Van Vollenhoven, Ronald F ^g   Lampa, Jon ^g   Saito, Kazuyoshi ^h   Tanaka, Yoshiya ^h   Genovese, Mark C ^a   Klareskog, Lars ^g   Gregersen, Peter K ^c   Robinson, William H ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d JOSLIN DIABETES CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f STANFORD UNIVERSITY   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCALPASTATIN; APOLIPOPROTEIN E; AUTOANTIBODY; BIGLYCAN; CALPASTATIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CLUSTERIN; CYTOKINE; DECORIN; EOTAXIN; ETANERCEPT; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 2; FIBROMODULIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE 6 PHOSPHATE ISOMERASE; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 60; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SERINE PROTEINASE; SERINE PROTEINASE 11; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIMENTIN; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN ANALYSIS; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG ANTAGONISM; IMMUNOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649392488     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2706     Document Type: Article

References (31)

1. Feldmann M Maini R Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics Immunol Rev 2008, 223:7-19. 10.1111/j.1600-065X.2008.00626.x 18613827
2. Felson DT Anderson JJ Boers M Bombardier C Furst D Goldsmith C Katz LM Lightfoot R Jr Paulus H Strand V Tugwell P Weinblatt M Williams HJ Wolfe W Kieszak American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 1995, 38:727-735. 10.1002/art.1780380602 7779114
3. Maini R St Clair E Breedveld F Furst D Kalden J Weisman M Smolen J Emery P Harriman G Feldmann M Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial Lancet 1999, 354:1932-1939. 10.1016/S0140-6736(99)05246-0 10622295
4. Weinblatt M Keystone E Furst D Moreland L Weisman M Birbara C Teoh L Fischkoff S Chartash E Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial Arthritis Rheum 2003, 48:35-45. 10.1002/art.10697 12528101
5. Weinblatt ME Kremer JM Bankhurst AD Bulpitt KJ Fleischmann RM Fox RI Jackson CG Lange M Burge DJ A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 1999, 340:253-259. 10.1056/ NEJM199901283400401 9920948
6. Felson D Anderson J Lange M Wells G LaValley M Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998, 41:1564-1570. 9751088
7. Kievit W Fransen J Oerlemans AJ Kuper HH Laar van der MA de Rooij DJ De Gendt CM Ronday KH Jansen TL van Oijen PC Brus HL Adang EM van Riel PL The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice Ann Rheum Dis 2007, 66:1473-1478. 10.1136/ard.2007.072447 17426065
8. Weaver AL Lautzenheiser RL Schiff MH Gibofsky A Perruquet JL Luetkemeyer J Paulus HE Xia HA Leff JA Investigators TR Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: Results from the RADIUS observational registry Curr Med Res Opin 2006, 22:185-198. 10.1185/030079905X65510 16393444
9. Chen Y Jobanputra P Barton P Jowett S Bryan S Clark W Fry-Smith A Burls A A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Health Technol Assess 2006, 10:1-229. 17049139
10. Zink A Strangfeld A Schneider M Herzer P F H Stoyanova-Scholz M Wassenberg S Kapelle A Listing J Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials Arthritis Rheum 2006, 54:3399-3407. 10.1002/ art.22193 17075823
11. Ranganathan P Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis Pharmacogenomics 2005, 6:481-490. 10.2217/ 14622416.6.5.481 16013998
12. Hueber W Tomooka BH Zhao X Kidd BA Drijfhout JW Fries JF van Venrooij WJ Metzger AL Genovese MC Robinson WH Proteomic analysis of secreted proteins in early rheumatoid arthritis: Anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines Ann Rheum Dis 2007, 66:712-719. 10.1136/ard.2006.054924 16901957
13. Robinson WH DiGennaro C Hueber W Haab BB Kamachi M Dean EJ Fournel S Fong D Genovese MC de Vegvar HE Skriner K Hirschberg DL Morris RI Muller S Pruijn GJ van Venrooij WJ Smolen JS Brown PO Steinman L Utz PJ Autoantigen microarrays for multiplex characterization of autoantibody responses Nat Med 2002, 8:295-301. 10.1038/nm0302-295 11875502
14. Hueber W Kidd BA Tomooka BH Lee BJ Bruce B Fries JF Sonderstrup G Monach P Drijfhout JW van Venrooij WJ Utz PJ Genovese MC Robinson WH Antigen microarray analysis defines subtypes of rheumatoid arthritis Arthritis Rheum 2005, 52:2645-2655. 10.1002/art.21269 16142722
15. Arnett F Edworthy S Bloch D McShane D Fries J Cooper N Healey L Kaplan S Liang M Luthra H The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302 3358796
16. Eisen Lab http://rana.lbl.gov/EisenSoftware.htm
17. Tibshirani R Hastie T Narasimhan B Chu G Diagnosis of multiple cancer types by shrunken centroids of gene expression Proc Natl Acad Sci USA 2002, 99:6567-6572. 124443 12011421 10.1073/pnas.082099299
18. PAM: Prediction Analysis for Microarrays http://www-stat.stanford.edu/ ~tibs/PAM/index.html
19. The R Project for Statistical Computing http://www.r-project.org/
20. Van Vollenhoven R Klareskog L Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: Data from the Stockholm Tumor Necrosis Factor alpha Followup Registry Arthritis Rheum 2003, 48:1500-1503. 10.1002/art.11027 12794816
21. Buch M Seto Y Bingham S Bejarano V Bryer D White J Emery P C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept Arthritis Rheum 2005, 52:42-48. 10.1002/art.20711 15641046
22. Liu C Batliwalla F Li W Lee A Roubenoff R Beckman E Khalili H Damle A Kern M Plenge RM Coenen MJ Behrens TW Carulli JP Gregersen PK Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis Mol Med 2008, 14:575-581. 18615156 2443997
23. Tutuncu Z Kavanaugh A Zvaifler N Corr M Deutsch R Boyle D Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents Arthritis Rheum 2005, 52:2693-2696. 10.1002/ art.21266 16142749
24. Seitz M Wirthmuller U Moller B Villiger PM The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNF alpha-blockers in rheumatoid arthritis and spondyloarthritis patients Rheumatology 2007, 46:93-96. 10.1093/rheumatology/kel175 16720636
25. Potter C Hyrich KL Tracey A Lunt M Plant D Symmons DP Thomson W Worthington J Emery P Morgan AW Wilson AG Isaacs J Barton A BRAGGSS Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis Ann Rheum Dis 2009, 68:69-74. 2596303 18375541 10.1136/ ard.2007.084715
26. Rifai N Gillette M Carr S Protein biomarker discovery and validation: the long and uncertain path to clinical utility Nat Biotechnol 2006, 24:971-983. 16900146 10.1038/nbt1235
27. O'Dell JR Therapeutic strategies for rheumatoid arthritis N Engl J Med 2004, 350:2591-2602. 10.1056/NEJMra040226 15201416
28. Fabre S D AM Dossat N Guisset C Cohen J Cristol J Daures J Jorgensen C Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis Clin Exp Immunol 2008. 18549443
29. Braun-Moscovici Y Markovits D Zinder O Schapira D Rozin A Ehrenburg M Dain L Hoffer E Nahir A Balbir-Gurman A Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis J Rheumatol 2006, 33:497-500. 16511906
30. Vis M Bos W Wolbink G Voskuyl A Twisk J Stadt Van de R Hamann D Dijkmans B Lems W IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis J Rheumatol 2008, 35:425-428. 18322974
31. Smolen J Aletaha D Grisar J Redlich K Steiner G Wagner O The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: Where are we now? Arthritis Res Ther 2008, 10:208. 2483438 18557991 10.1186/ar2418